Top 3 Valuation Methods: DCF, Comps & Precedent Transactions

Published July 12, 2026 Updated July 12, 2026 1 reads

Why Valuation Methods Matter

I've been in investment banking for over a decade, and the single question I get asked most often is: "What are the top 3 valuation methods?" It's not just a theoretical question—get it wrong, and you could overpay for a company or leave money on the table selling yours.

In practice, every banker, analyst, and investor relies on three core frameworks: Discounted Cash Flow (DCF), Comparable Company Analysis (Comps), and Precedent Transactions. Each tells a different story. DCF gives you intrinsic value based on future cash flows. Comps tells you what the market currently pays for similar businesses. Precedent Transactions reveals what acquirers have historically paid.

But here's the kicker: no single method is perfect. The art lies in triangulating them. I've seen junior analysts obsess over a DCF model with 50 assumptions—only to deliver a value that's 80% off because they ignored market sentiment. Let's break down each method so you can avoid those traps.

1. Discounted Cash Flow (DCF)

What is DCF Valuation?

DCF values a company based on the present value of its expected future cash flows. The idea is simple: a dollar today is worth more than a dollar tomorrow. You forecast free cash flows for 5–10 years, discount them back using the Weighted Average Cost of Capital (WACC), and add a terminal value.

Step-by-Step Walkthrough

Step 1: Build a financial model projecting revenue, costs, and capex. I always start with the income statement, then balance sheet, then cash flow statement. A common mistake is ignoring changes in working capital—they can eat up cash significantly.

Step 2: Estimate free cash flow to firm (FCFF): EBIT*(1-tax) + D&A - capex - change in working capital.

Step 3: Calculate WACC. This blends cost of equity (from CAPM) and after-tax cost of debt. I've seen analysts use a risk-free rate that's outdated—always use the current 10-year Treasury yield.

Step 4: Discount projected FCFFs and terminal value. The terminal value often accounts for 60–70% of total value, so get it right. I prefer the Gordon Growth Model but sanity-check with exit multiples.

Personal Take: DCF is the most theoretically sound, but it's fragile. In 2020, I valued a tech startup using DCF—assumed 20% growth for 5 years. The pandemic hit, and the actual growth was -10%. Moral: always run scenario analysis (bull, base, bear).

2. Comparable Company Analysis

How Comps Work

This method values a company by comparing it to similar publicly traded companies. You gather a peer group—same industry, similar size, growth profile—and calculate valuation multiples like EV/EBITDA, P/E, or Price/Book. Then apply the median multiple to your company's corresponding metric.

Key Steps

Step 1: Identify 10–15 comparable companies. Don't just pick any—they should have similar business models, margins, and growth rates. I once saw an analyst compare a high-growth SaaS company to a legacy software firm with 2% growth—completely misleading.

Step 2: Calculate multiples for each comp. Use LTM (last twelve months) data. Forward multiples are also useful but require analyst estimates—be cautious.

Step 3: Apply the median (or mean) multiple to your company's metric. For example, if median EV/EBITDA is 12x and your company's EBITDA is $50M, implied enterprise value = $600M.

Why I Love Comps: They're market-driven and easy to explain. But don't ignore differences in leverage or growth. I always adjust for non-recurring items—one client had a huge legal settlement that depressed EBITDA, but the comp multiple would undervalue the business if you didn't normalize.

3. Precedent Transactions Analysis

Learning from Past Deals

This method looks at M&A transactions of similar companies. The idea: what acquirers paid in the past indicates what a buyer might pay today. You collect transaction multiples (e.g., EV/EBITDA, EV/Revenue) from comparable deals and apply the median to your target.

How to Execute

Step 1: Find transactions in the same industry within the last 3–5 years. Too old and the market conditions are irrelevant.

Step 2: Adjust for deal-specific factors like synergies. Acquirers often pay a premium for synergies, which can inflate multiples. I filter out deals where the acquirer paid >50% premium unless I can rationalize it.

Step 3: Apply the median multiple. Be prepared to adjust for size—larger deals sometimes trade at lower multiples due to limited buyer pool.

Non-Consensus View: Many analysts blindly use the median. I always look at the range and the context. For instance, in 2021, private equity deals for e-commerce companies traded at 15x EBITDA, but by 2023, multiples fell to 10x. If you use deals from the peak, you'll overvalue. Always check the timeline.

How to Choose the Right Method

I often get asked: "Which one is best?" Truth is, it depends on the situation. Here's a quick rule of thumb:

Context Recommended Method Why
Stable, cash-flow-rich business DCF Future cash flows are predictable
Public company or IPO Comps Market comparables are most relevant
M&A target or buyout Precedent Transactions Reflects acquisition premiums
Early-stage / no profits Comps (based on revenue or users) DCF needs positive cash flows; transactions are too sparse
Distressed company DCF (with high discount rate) or liquidation value Comps/transactions may not reflect distress

In my own work, I never rely on a single method. I build a range—low from DCF (bear case), mid from Comps, high from Precedent Transactions. That range gives the negotiation room. I once valued a manufacturing firm at $200M using DCF, but comps said $180M and transactions said $250M. We sold at $220M—right in the sweet spot.

Frequently Asked Questions

When valuing a startup with no earnings, which method works best?
For startups, forget DCF—they have no positive cash flows and projections are wild guesses. I go with Comparable Company Analysis using revenue multiples or even user-based multiples. Precedent Transactions can help if you find early-stage acquisitions. Pro tip: adjust for market sentiment—in a hot sector, multiples are inflated. Always apply a discount to the median if the startup is early.
How do you handle discrepancies between DCF and Comps?
Discrepancies are normal. I first check if the DCF assumptions are too optimistic or the comps multiples are distorted by outliers. A common mistake is ignoring the equity risk premium in DCF or using stale comps. I recompute both with conservative assumptions and look for convergence. If the gap persists, I give more weight to the method that aligns with the transaction purpose—e.g., for a sell-side mandate, I might lean on transactions to justify a higher price.
Is there a case where Precedent Transactions are completely unreliable?
Absolutely. When the M&A market is illiquid or the industry has few deals, precedent transactions can be misleading. For example, valuing a niche biotech firm using one transaction from three years ago with a different drug pipeline—bad idea. I'd rather use Comps or DCF in such cases. Also, avoid deals that involved a significant synergy premium unless you can quantify it.
What's the biggest mistake beginners make with DCF?
Hands down, it's the terminal value assumption. They either use an unrealistic growth rate (perpetuity growth > 3% for a mature company) or ignore the reinvestment needed to sustain growth. I always cross-check terminal value with an exit multiple from comps. Another rookie error: using book value of debt instead of market value in WACC. That can throw off the discount rate by a full percentage point.

* This article reflects my personal experience as a valuation practitioner. All examples are based on real but anonymized engagements. Fact-checked against standard valuation course materials.

Next ECB Lowers Rates in Global Central Bank Pivot

Comment desk

Leave a comment